The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value

References

• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. Published online. 2017;12(5):e0177113.
   PubMed Web of Science ®Google Scholar
• Wouters I, Desmet S, Van Heirstraeten L, et al. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Vaccine. 2019;37(8):1080–1086.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Heal. 2018;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Belgian superior health council: vaccination against pneumococci - guidelines in children (HGR 9519). 2018 Accessed 10 December 2020. Available from: https://www.health.belgium.be/nl/advies-9519-vaccinatie-tegen-pneumokokken-kinderen#anchor-34691.
   Google Scholar
• Berete F, Tafforeau J, and Demarest S, et al. Gezondheidsenquête 2018: vaccinatie. Brussel, België: Sciensano Accessed 10 December 2020; Rapportnummer: D/2019/14.440/82. Rapportnummer: D/2019/14.440/82: www.gezondheidsenquete.be.
   Google Scholar
• Thompson A, Lamberth E, Severs J, et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019;37(42):6201–6207.
   PubMed Web of Science ®Google Scholar
• Pfizer [Internet]. New York; 2021 [updated 13/August/2021; cited 2021 August 13]; Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent.
   Google Scholar
• Merck [Internet]. KENILWORTH, N.J. 2021 [updated 2021 August 13]; Available from: https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adul.
   Google Scholar
• Desmet S, Lagrou K, Wyndham-Thomas C, et al. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2021;21(1):127–136.
   PubMed Web of Science ®Google Scholar
• Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15(1):1–10.
   PubMedGoogle Scholar
• Desmet S, Verhaegen J, Van Ranst M, et al. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. Published online. 2018;18(8):830–831.
   PubMed Web of Science ®Google Scholar
• Report National Reference Centre Streptococcus pneumoniae. 2017. UZ Leuven: National reference centre for invasive S. pneumoniae; Published online 2018.
   Google Scholar
• Mendes E, Grammens T, Litzroth A, et al. Infectieziekten bij kinderen die voorkomen kunnen worden door vaccinatie. Jaarraport. 2015. Wetenschappelijk Instituut Volksgezondheid.:104.
   Google Scholar
• Wouters I, Van Heirstraeten L, Desmet S, et al. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. Vaccine. Published online. 2018;36(1):15–22.
   PubMed Web of Science ®Google Scholar
• Wouters I, Desmet S, Van Heirstraeten L, et al. How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Euro Surveill. 2020;25(5). DOI:10.2807/1560-7917.ES.2020.25.5.1900303
   PubMedGoogle Scholar
• Report National Reference Centre Streptococcus pneumoniae 2019. UZ Leuven: National Reference Centre for Invasive S. pneumoniae; Published online 2020.
   Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):1–18.
   Web of Science ®Google Scholar
• Kraicer-melamed H, Donnell SO, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. 2016;34(13):1540–1550.
   PubMed Web of Science ®Google Scholar
• Winje BA, Berild JD, Vestrheim DF, et al. “Efficacy and effectiveness of pneumococcal vaccination in adults – an update of the literature”. [Effekt av pneumokokkvaksine hos eldre] Report 2019. Oslo: Norwegian Institute of Public Helath, 2019.
   Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125.
   PubMed Web of Science ®Google Scholar
• Van Deursen AMM, Van Houten MA, Webber C, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the community-acquired pneumonia immunization trial in adults (capita). Clin Infect Dis. 2017;65(5):787–795.
   PubMed Web of Science ®Google Scholar
• Van Werkhoven CH, Huijts SM, Bolkenbaas M, et al. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis. 2015;61(12):1835–1838.
   PubMed Web of Science ®Google Scholar
• Tin Htar M T, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12(5):1–16.
   Web of Science ®Google Scholar
• Berical AC, Harris D, Dela Cruz CS, et al. Pneumococcal vaccination strategies: an update and perspective. Ann Am Thorac Soc. 2016;13(6):933–944.
   PubMed Web of Science ®Google Scholar
• Henckaerts L, Desmet S, and Schalck N, et al. The impact of childhood 13-valent pneumococcal conjugate vaccination on overall invasive pneumococcal disease, including the oldest old. Acta Clin Belgica Int J Clin Lab Med. 2020 76 4 ;272–279.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Invasive pneumococcal disease. In: ECDC. Annual epidemiological report for 2018. Stockholm: ECDC; 2020 1–11 .
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance systems overview [Internet]. Stockholm: ECDC. 2018 Accessed 10 December 2020. https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=40
   Google Scholar
• Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77(5):368–378.
   PubMed Web of Science ®Google Scholar
• Desmet S, Wouters I, Van HL, et al. In-depth analysis of pneumococcal serotypes in Belgian children (2015–2018): diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease. Vaccine. 2021;39(2):372–379.
   PubMed Web of Science ®Google Scholar
• Hurley D, Griffin C, Young M, et al. Safety, tolerability, and immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. Published online. 2020;1–9. DOI:10.1093/cid/ciaa1045.
   Google Scholar
• Report National Reference Centre Streptococcus pneumoniae 2018. UZ Leuven: National reference centre for invasive S. pneumoniae; Published online 2019.
   Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451.
   PubMed Web of Science ®Google Scholar
• Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clin Infect Dis. 2019;68(12):2135–2143.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: a systematic review and pooled analysis. Vaccine. 2019;37(43):6310–6316.
   PubMed Web of Science ®Google Scholar
• Weinberger R, van der Linden M, Imöhl M, et al. Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule. Vaccine. 2016;34(18):2062–2065.
   PubMed Web of Science ®Google Scholar
• Stacey HL, Rosen J, Peterson JT, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccines Immunother. 2019;15(3):530–539.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–6891.
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Ouldali N, et al. Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation. Clin Infect Dis. Published online. 2020;13–16. DOI:10.1093/cid/ciaa917.
   Web of Science ®Google Scholar
• Kavalari ID, Fuursted K, Krogfelt KA, et al. Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 24F in Denmark. Sci Rep. 2019;9(1):1–9.
   PubMedGoogle Scholar
• Ludwig G, Garcia-Garcia S, Lanaspa M, et al. Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): surveillance data from 23 sites in Catalonia, Spain. PLoS One. 2020;15(2):1–16.
   Web of Science ®Google Scholar
• Ouldali N, Levy C, Varon E, et al. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect Dis. 2018;18(9):983–991.
   PubMed Web of Science ®Google Scholar
• Vadlamudi NK, Parhar K, Altre Malana KL, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: a systematic review and meta-analysis. Vaccine. 2019;37(8):1021–1029.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Prevanar 13. Procedure no. EMEA/H/C/001104/II/0028 London: European Medicines Agency, 2011.
   Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–846.
   PubMed Web of Science ®Google Scholar
• Masomian M, Ahmad Z, Gew LT, et al. Development of next generation streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel). 2020;8(1):1–23.
   Web of Science ®Google Scholar